Q-omics provides the consensus-scored GAB1 profile across patient tissues and cancer cell-line models. GAB1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GAB1 is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, GAB1 protein abundance shows 26,835 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, COAD, and LUAD as cancer lineages where GAB1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GAB1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GAB1 survival associations across molecular data types. GAB1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GAB1 RNA expression–survival associations across cancer types. High GAB1 expression shows unfavorable associations in UVM, but favorable associations in KIRC, MESO, BRCA, KIRP and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GAB1 RNA expression.
This table summarizes GAB1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 7. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GAB1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GAB1 shows lower tumor expression in COAD, LUAD, KICH, THCA, UCEC and LUSC. The COAD box plot shows higher GAB1 RNA expression in normal versus tumor tissue (log2 FC = −1.145, t-test p < 0.001).
This table shows molecular features associated with GAB1 in patient tissues and cancer cell lines. In patient samples, GAB1 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, GAB1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
